

## Molecular docking-based design and development of a highly selective probe substrate for UDP-glucuronosyltransferase 1A10

Risto Olavi Juvonen, Sanna Rauhamäki, Sami Kortet, Sanna P. Niinivehmas, Johanna Troberg, Aleksanteri Petsalo, Juhani Huuskonen, Hannu Raunio, Moshe Finel, and Olli T. Pentikainen

*Mol. Pharmaceutics*, **Just Accepted Manuscript** • DOI: 10.1021/acs.molpharmaceut.7b00871 • Publication Date (Web): 08 Feb 2018

Downloaded from <http://pubs.acs.org> on February 14, 2018

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



**Molecular docking-based design and development of a highly selective probe  
substrate for UDP-glucuronosyltransferase 1A10**

<sup>1</sup>Risto O. Juvonen, <sup>2</sup>Sanna Rauhamäki, <sup>2,3</sup>Sami Kortet, <sup>2</sup>Sanna Niinivehmas, <sup>4</sup>Johanna Troberg, <sup>1</sup>Aleksanteri Petsalo, <sup>3</sup>Juhani Huuskonen, <sup>1</sup>Hannu Raunio, <sup>4</sup>Moshe Finel, <sup>2,5</sup>Olli T. Pentikäinen

1 School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Box 1627, FI-70211 Kuopio, Finland

2 University of Jyväskylä, Department of Biological and Environmental Science, P.O. Box 35, FI-40014 University of Jyväskylä, Finland

3 University of Jyväskylä, Department of Chemistry, P.O. Box 35, FI-40014 University of Jyväskylä, Finland

4 Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 University of Helsinki, Finland

5 Institute of Biomedicine, Faculty of Medicine, University of Turku, FI-20014 University of Turku, Finland

\* Corresponding authors: [risto.juvonen@uef.fi](mailto:risto.juvonen@uef.fi) (in vitro), [olli.pentikainen@utu.fi](mailto:olli.pentikainen@utu.fi) (modeling and synthesis)

Keywords: 7-hydroxycoumarin, UDP-glucuronosyltransferase, glucuronidation, in silico, fluorescence, drug metabolism

**Abstract**

Intestinal and hepatic glucuronidation by the UDP-glucuronosyltransferases (UGTs) greatly affect the bioavailability of phenolic compounds. UGT1A10 catalyzes glucuronidation reactions in the intestine, but not in the liver. Here, our aim was to develop selective, fluorescent substrates to easily elucidate UGT1A10 function. To this end, homology models were constructed, used to design new substrates and subsequently six novel C3 substituted (4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 4-dimethylaminophenyl, 4-methylphenyl or triazole) 7-hydroxycoumarin derivatives were synthesized from inexpensive starting materials. All tested compounds could be glucuronidated to non-fluorescent glucuronides by UGT1A10, four of them highly selectively by this enzyme. A new UGT1A10 mutant, 1A10-H210M, was prepared based on the newly constructed model. Glucuronidation kinetics of the new compounds, in both wild-type and mutant UGT1A10 enzymes, revealed variable effects of the mutation. All six new C3 substituted 7-hydroxycoumarins were glucuronidated faster by human intestine than by liver microsomes supporting the results obtained with recombinant UGTs. The most selective 4-dimethylaminophenyl and triazole C3 substituted 7-hydroxycoumarins could be very useful substrates in studying the function and expression of the human UGT1A10.

**Keywords:** 7-hydroxycoumarin derivative, UDP-glucuronosyltransferase, in silico, fluorescence, drug metabolism

## Introduction

The extents of absorption and first-pass metabolism in the intestine and liver strongly affect the bioavailability of drugs and other orally ingested xenobiotic compounds <sup>1-2</sup>. Although hepatic metabolism is the major determinant of first-pass metabolism for most drugs, intestinal metabolism is critical for the bioavailability of certain compounds, particularly those that could be directly conjugated, like phenols and flavonoids <sup>3-5</sup>. Such xenobiotics typically contain a nucleophilic functional group, usually a hydroxyl group, that can accept an endogenous conjugating moiety, particularly glucuronic acid or sulfone. More rarely the conjugating group is methyl, acetyl or amino acid <sup>6</sup>.

The UDP-glucuronosyltransferase enzymes (UGTs, EC 2.4.1.17) catalyze about 35% of the drug conjugation reactions and are abundantly expressed among the intestinal conjugating enzymes <sup>4-5, 7</sup>. They catalyze transfer of the glucuronic acid moiety from UDP-glucuronic acid cofactor onto hydroxyl, amine, carboxylic acid, thiol or thioacid groups of the aglycone substrates, reactions that are commonly called glucuronidation <sup>8</sup>. There is a significant difference in the expression profile of individual UGTs between the intestine and liver <sup>9-11</sup>. While about ten different UGTs are abundantly expressed in the liver, only UGT1A1, UGT1A10, UGT2B7 and UGT2B17 are expressed in the small intestine to significant amounts at the protein level <sup>10, 12-14</sup>. Unfortunately, the high activity and importance of the intestinal UGT1A10 was (and still is) often underestimated due to common use of poorly-active commercial UGT1A10 <sup>13</sup>.

UGT1A10 glucuronidates many drugs and xenobiotics <sup>13, 15-17</sup>. Glucuronidation of estriol at the 3-OH and of estrone could be used as selective reactions for UGT1A10, but their measurements require chromatographic separation of the resulting glucuronide from the substrate <sup>16, 18</sup>. Likewise, dopamine is a UGT1A10 selective substrate, but its low affinity<sup>19</sup>

has limited its use to qualitative measurements only<sup>14</sup>. Accordingly, availability of more convenient marker substrates for UGT1A10 would foster evaluation of glucuronidation reactions, particularly if the assays were easy and fast to perform.

The interactions between substrates and xenobiotic metabolizing enzymes are increasingly being studied by in silico modeling<sup>20-23</sup>. Currently, the lack of crystal structures of the N-terminal domain of any mammalian UGT impedes structure-activity relationship and mechanistic studies. UDP-glucuronic acid binds at the C-terminal domain, which is highly homologous among different UGTs and evolutionary conserved. The structure of the latter domain has been solved by X-ray crystallography<sup>24</sup>. However, that available crystal structure does not provide sufficient data to predict binding of acceptor substrates, e.g. a drug molecule, as substrates bind to the N-terminal domain, which is more variable than the C-terminal domain among UGT enzymes. In silico models for this domain were constructed previously<sup>20-21</sup>, but we need better ones in order to analyze substrate-enzyme interactions in UGTs at the atomic level.

The hydroxyl group at C7 on the coumarin scaffold renders the compound fluorescent and glucuronidation of this hydroxyl abolishes the fluorescence (Figure 1)<sup>25</sup>. Substituents at positions such as C3 or C4 of the coumarin do not quench the 7-hydroxycoumarin derivatives' fluorescence, but modify its intensity, depending on the substituent's chemical nature. The 7-hydroxyl group on coumarin is also a good functional group for glucuronidation by many UGTs. Therefore, fluorescent 7-hydroxycoumarin derivatives provide an opportunity to design novel fluorescent substrates for UGTs, using molecular modelling as the starting point.

[Figure 1]

1  
2  
3 In this study, we first constructed homology models for all the human UGT enzymes of  
4 subfamily 1A and used them to design fluorescent 7-hydroxycoumarin derivatives *in silico*.  
5  
6 We then synthesized six compounds and developed a convenient multiwell plate assay  
7  
8 protocol, based on fluorescence decrease, to test their glucuronidation rate. The results led to  
9  
10 the identification of several 3-substituted 7-hydroxycoumarins as selective substrates for the  
11  
12 human UGT1A10. A UGT1A10 mutant was prepared based on the model and as a test for it.  
13  
14 Subsequently, glucuronidation kinetic analyses of the 3-substituted 7-hydroxycoumarins, by  
15  
16 wild-type and mutant UGT1A10, were carried out using the same multiwell plate assay  
17  
18 protocol.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Experimental section

**Materials:** Alamethicin, trichloroacetic acid, UDPGA sodium salt, 7-hydroxycoumarin (99%), 7-hydroxy-(4-trifluoromethyl)coumarin (99%) and bovine serum albumin were from Sigma-Aldrich (Mannheim, Germany). Formic acid (99 %) and  $\text{MgCl}_2$  were from Riedel-de Haen (Vantaa, Finland). Acetonitrile (Ultra gradient HPLC grade), methanol (HPLC gradient grade) and glycine were from J.T. Baker (Deventer, the Netherlands). Ethanol ( $\geq 99.5$  %, Etax Aa) was from Altia (Helsinki, Finland). Water was deionized by MilliQ gradient A10.

## Methods

**Modeling.** To enable structure-based design of UGT1A10 selective substrates, all nine UGT1A-enzymes were modeled. Sequences of human UGT1A enzymes were gathered from the UniProt Knowledgebase at [www.uniprot.org](http://www.uniprot.org) (UniProt Consortium, 2015). The accession codes for the retrieved UGT1As were: Q9HAW8 (1A10), O60656 (1A9), Q9HAW9 (1A8), Q9HAW7 (1A7), P19224 (1A6), P35504 (1A5), P22310 (1A4), P35503 (1A3) and P22039 (1A1). To identify template protein structures for homology modeling purposes, the retrieved UGT sequences were used in blast searches against the protein data bank (PDB) structures. Based on the results of these searches, structures 2O6L<sup>24</sup>, 3HBF<sup>26</sup>, 3WC4<sup>27</sup> and 2C1Z<sup>28</sup> were selected as templates for homology modeling. The sequence alignment for the modeling was produced in two steps. First a protein structure-based sequence alignment was derived for the selected four protein structures by using Vertaa in Bodil<sup>29</sup> and the 2C1Z-structure as a template, since it gave the best match for UGT1A10 and contained both the N- and C-termini. In the second step the above listed nine UGT1A sequences were aligned, using Bodil, against the structural alignment, using STRMAT110 matrix<sup>30</sup> with 40 as the gap penalty. The alignment was adjusted for occasional variations in sequence length and used to


create models for each UGT1A, as well as in model construction that was performed using Modeller version 9.15<sup>31</sup>.

**Molecular docking.** The ligands that were selected for docking studies were prepared by using LigPrep (version 3.3, Schrödinger, LLC, New York, NY, 2015). The shapes and electrostatic properties of the substrate binding sites of modeling-produced UGT1A enzymes were analysed with Panther<sup>32</sup> and molecular docking was performed with PLANTS<sup>33</sup>.

**Synthesis.** All the synthesis reactions were carried out using commercial materials and reagents without further purification, unless otherwise noted. Reaction mixtures were heated using the CEM Discovery microwave apparatus. All reactions were monitored by thin layer chromatography (TLC) on silica gel plates. <sup>1</sup>H NMR and <sup>13</sup>C NMR data were recorded on a Bruker Avance 400 MHz spectrometer or Bruker Avance III 300 MHz spectrometer. Chemical shifts are expressed in parts per million values (ppm) and are designated as s (singlet), br s (broad singlet), d (doublet), dd (doublet), t (triplet). Coupling constants (*J*) are expressed as values in hertz (Hz). The mass spectra were recorded using Micromass LCT ESI-TOF equipment. Elemental analyses were done with Elementar Vario EL III elemental analyzer. All compounds tested present more than 95 % purity.

### General procedure for the synthesis of coumarin derivatives

The coumarin derivatives **1-6** were synthesized using Perkin-Oglialor condensation reaction (Scheme 1). The method was developed from the earlier published procedures and transferred to a microwave reactor.<sup>34</sup>



Scheme 1. The general procedure for the synthesis of coumarin derivatives

A typical procedure: a mixture of salicylaldehyde derivative (2 mmol) and phenyl acetic acid derivative (2.1 mmol), acetic acid anhydride (0.6 ml) and triethylamine (0.36 ml) were placed in a microwave reactor tube and heated at 100-170 °C in the microwave apparatus for 10-20 min. After cooling, 2 ml of 10% NaHCO<sub>3</sub> solution was added and the precipitate was filtered, dried and recrystallized from EtOH/H<sub>2</sub>O or acetone/H<sub>2</sub>O mixture. The acetyl group(s) were removed by treating the compound with MeOH/NaOH(aq) solution for 30-60 min at r.t. The solution was acidified with HCl (aq.) and the precipitate was filtered and recrystallized if needed. Experimental data for 7-acetoxy-3-(4-fluorophenyl)-2*H*-chromen-2one, 7-hydroxy-3-(4-fluorophenyl)-2*H*-chromen-2-one (**1**), 7-acetoxy-3-(4-acetoxyphenyl)-2*H*-chromen-2one, 7-hydroxy-3-(4-hydroxyphenyl)-2*H*-chromen-2one (**2**), and 7-acetoxy-3-(4-methoxyphenyl)coumarin, 7-hydroxy-3-(4-methoxyphenyl)coumarin (**3**) were already published elsewhere.<sup>34</sup>

7-hydroxy-3-(4-(dimethylamino)phenyl)-2*H*-chromen-2-one (**4**)<sup>35</sup>

In the first step 7-acetoxy-3-(4-(dimethylamino)phenyl)-2*H*-chromen-2one was obtained.

Yield: 70%; <sup>1</sup>H-NMR (400 MHz, d<sup>6</sup>-DMSO) δ: 2.31 (s, 3H, CH<sub>3</sub>CO), 2.95 (s, 6H, (CH<sub>3</sub>)<sub>2</sub>N-), 6.77 (d, *J*<sup>3</sup> = 9.0 Hz, 2H, H-2', H-6'), 7.14 (dd, *J*<sup>3</sup> = 8.4 Hz, *J*<sup>4</sup> = 2.2 Hz, 1H, H-5), 7.26 (d, *J*<sup>4</sup> = 2.2 Hz, 1H, H-8), 7.63 (d, *J*<sup>3</sup> = 9.0 Hz, 2H, H-3', H-5') 7.76 (d, *J*<sup>3</sup> = 8.5 Hz, 1H, H-5), 8.11 (s, 1H, H-4); <sup>13</sup>C-NMR (100.6 MHz, d<sup>6</sup>-DMSO) δ: 20.85, 39.84, 109.44, 111.58, 117.76, 118.57, 121.57, 126.00, 128.82, 129.11, 136.46, 150.45, 151.90, 152.77, 159.74, 168.85.

In the second step 7-hydroxy-3-(4-(dimethylamino)phenyl)-2*H*-chromen-2one (**4**) was obtained.

Yield: 85% yellow solid;  $^1\text{H-NMR}$  (400 MHz,  $\text{d}^6\text{-DMSO}$ )  $\delta$ : 2.94 (s, 6H,  $(\text{CH}_3)_2\text{N-}$ ), 6.72 (d,  $J^4 = 2.3$  Hz, 1H, H-8), 6.75 (d,  $J^3 = 9.0$  Hz, 2H, H-2', H-6'), 6.79 (dd,  $J^3 = 8.4$  Hz,  $J^4 = 2.3$  Hz, 1H, H-5), 7.55 (d,  $J^3 = 8.5$  Hz, 1H, H-5), 7.58 (d,  $J^3 = 9.0$  Hz, 2H, H-3', H-5'), 7.99 (s, 1H, H-4);  $^{13}\text{C-NMR}$  (100.6 MHz,  $\text{d}^6\text{-DMSO}$ )  $\delta$ : 39.92, 101.59, 112.33, 113.16, 122.30, 122.32, 129.34, 137.83, 150.07, 154.27, 160.30, 160.41. ESI-MS:  $m/z$  (rel. abund. %) 304 ( $\text{M} + \text{Na}^+$ ); elemental anal. for  $\text{C}_{17}\text{H}_{15}\text{N}_1\text{O}_3$ , calc. C% 72.58, H% 5.37, N% 4.98, found C% 72.45, H% 5.40, N% 5.15.

### 7-hydroxy-3-(*p*-tolyl)-2H-chromen-2-one (**5**)<sup>36</sup>

In the first step 7-acetoxy-3(*p*-tolyl)-2H-chromen-2one was obtained.

Yield: 70%;  $^1\text{H-NMR}$  (300 MHz,  $\text{d}^6\text{-DMSO}$ )  $\delta$ : 2.32 (s, 3H,  $\text{CH}_3\text{CO}$ ), 2.35 (s, 3H,  $\text{CH}_3\text{-Ph}$ ), 7.17 (dd,  $J^3 = 8.4$  Hz,  $J^4 = 2.2$  Hz 1H, H-6), 7.27 (d,  $J^3 = 8.0$  Hz, 2H, H-2', H-6'), 7.29 (d,  $J^4 = 2.2$  Hz, 1H, H-8), 7.63 (d,  $J^3 = 8.2$  Hz, 2H, H-3', H-5') 7.80 (d,  $J^3 = 8.5$  Hz, 1H, H-5), 8.21 (s, 1H, H-4);  $^{13}\text{C-NMR}$  (100.6 MHz,  $\text{d}^6\text{-DMSO}$ )  $\delta$ : 20.77, 20.82, 109.56, 117.37, 118.66, 125.99, 128.25, 128.76, 129.30, 131.60, 138.09, 139.37, 152.51, 153.28, 159.47, 168.74.

In the second step 7-hydroxy-3(*p*-tolyl)-2H-chromen-2one (**5**) was obtained

Yield: 85% brownish solid;  $^1\text{H-NMR}$  (300 MHz,  $\text{d}^6\text{-DMSO}$ )  $\delta$ :  $^{13}\text{C-NMR}$  (75 MHz,  $\text{d}^6\text{-DMSO}$ )  $\delta$ : 20.74, 101.65, 112.01, 113.30, 122.07, 128.04, 128.69, 129.80, 132.14, 137.37, 140.38, 154.77, 160.05, 161.05. ESI-MS:  $m/z$  (rel. abund. %) 275 ( $\text{M} + \text{Na}^+$ ); elemental anal. for  $\text{C}_{16}\text{H}_{12}\text{O}_3$ , calc. C% 76.18, H% 4.79, found C% 75.95, H% 4.83.

### 7-hydroxy-3-(1H-1,2,4-triazol-1-yl)-2H-chromen-2-one (**6**)

In the first step 2-oxo-3-(1H-1,2,4-triazol-1-yl)-2H-chromen-7-yl acetate was obtained.

Yield: 65% slightly brown solid; <sup>1</sup>H-NMR (400 MHz, d<sub>6</sub>-DMSO) δ: 2.33 (s, 3H, CH<sub>3</sub>-CO), 7.27 (dd, J<sub>3</sub> = 8.5 Hz, J<sub>4</sub> = 2.2 Hz, 1H, H-6), 7.44 (d, J<sub>4</sub> = 2.2 Hz 1H, H-8), 7.98 (d, J<sub>3</sub> = 8.5 Hz, 1H, H-5), 8.33 (s, 1H, H-3'), 8.61 (s, 1H, H-4), 9.20 (s, 1H, H-5'); <sup>13</sup>C-NMR (100.6 MHz, d<sub>6</sub>-DMSO) δ: 20.87, 110.02, 116.19, 119.50, 123.04, 130.10, 131.81, 144.40, 152.06, 152.21, 153.12, 155.73, 168.76. FT-IR (KBr, cm<sup>-1</sup>): 3416, 1723, 1617, 1208, 1129. mp. 190–192 °C. ESI-MS: m/z (rel. abund. %): calculated for (M + Na<sup>+</sup>)=294.0485, measured 294.0499, Δ=-1.4 mDa

In the second step the acetyl group was removed by treating the above mentioned compound with MeOH/K<sub>2</sub>CO<sub>3</sub> solution.

Yield: 92 % slightly brown solid; <sup>1</sup>H-NMR (400 MHz, d<sub>6</sub>-DMSO) δ: 6.85 (d, J<sub>4</sub> = 2.3 Hz, 1H, H-8), 6.90 (dd, J<sub>3</sub> = 8.5 Hz, J<sub>4</sub> = 2.3 Hz, 1H, H-6), 7.74 (d, J<sub>3</sub> = 8.6 Hz, 1H, H-5), 8.27 (s, 1H, H-3'), 8.49 (s, 1H, H-4), 9.10 (s, 1H, H-5'), 10.83 (br s, 1H, OH). <sup>13</sup>C-NMR (100.6 MHz, d<sub>6</sub>-DMSO) δ: 102.07, 110.42, 114.23, 119.72, 130.70, 134.11, 144.24, 151.78, 153.96, 156.37, 162.01. FT-IR (ATR, cm<sup>-1</sup>): 1724, 1623, 1511, 1328, 1129 811. mp. decomp. > 312 °C. ESI-MS: m/z (rel. abund. %): calculated for (M - H<sup>+</sup>)=228.0415, measured 228.0408, Δ=0.7 mDa

**UGTs and microsomes.** Recombinant human UGTs 1A1, 1A3, 1A6, 1A7, 1A8, 1A9, 1A10, 2A1, 2A2, 2A3, 2B4, 2B10, 2B7, and 2B17 were produced, as His-tagged proteins, in baculovirus-infected insect cells as previously described<sup>37-39</sup>. The relative expression level of each of these recombinant UGTs was evaluated by immunodetection, using monoclonal antibody against the His-tag, as described elsewhere<sup>40</sup>. A numeric value of 1.0 was given to the expression level of UGT1A8 and the relative expression level of each of the other UGTs was related to this value. Normalized activities were obtained by dividing the glucuronidation rate values by the relative expression level of the tested UGT. In addition, UGTs 1A4, 2B10

and 2B15 were purchased from Corning Life Sciences (New York, USA) and are marked, in Figure 5, with a “C” to indicate that they are commercial enzymes. The expression levels of the UGTs in the commercial samples could not be determined, so their protein concentration was used to calculate the reaction rate.

A commercial HLM pool (cat no:452210, BD Gentest, Bedford, MA, USA) and human intestine microsomes (HIM) pool (lot. no 1110189, XenoTech, Kansas City, KS, USA) were purchased. Pig liver samples were prepared from untreated female pigs that were used for practicing surgical procedures at the University of Kuopio (currently: University of Eastern Finland, Kuopio campus). Other animal liver microsomes were prepared as described previously<sup>41</sup>. The Ethics Committee for Animal Experiments, University of Kuopio approved these experiments.

### **Mutagenesis of UGT1A10**

The UGT1A10 mutant 1A10-H210M was prepared according to the QuikChange methodology, using the cloned UGT1A10 in pFastBac<sup>42</sup> as a template and the following two oligonucleotides:

1. 5'-ACTTTCAAGGAGAGAGTATGGAACATGATCGTGCACTTGGAGGACCATT-3'

2. 5'-AAATGGTCCTCCAAGTGCACGATCATGTTCCATACTCTCTCCTTGAAAGT-3'

The entire coding sequence of UGT1A10 in the mutant clone was sequenced and, subsequently, recombinant baculovirus was prepared and used to express the mutant enzyme in baculovirus-infected SF9 insect cells.

### **Absorbance and fluorescence spectra of C3 substituted 7-coumarins**

The absorbance spectra of 10  $\mu$ M coumarin derivatives at 100 mM Tris-HCl pH 7.4 containing 10 % dimethylsulfoxide were measured using a Hitachi U-2000 Spectrophotometer (Tokyo, Japan). Excitation and emission fluorescence spectra of 0.1  $\mu$ M coumarin derivatives in 100 mM Tris-HCl pH 7.4 were measured using a Shimadzu RF-5000 spectrofluorometer (Tokyo, Japan). The excitation spectra was from 200 to 420 nm at 460 nm emission and the emission spectra was from 400 to 600 nm at 390 nm excitation (Data in supplementary Table S1 and Figures S1 and S2). The effect of pH on fluorescence intensity was determined at 405 nm excitation and 460 nm emission, in the presence of either 1.5 % trichloroacetic acid, 100 mM phosphate buffers at pH 5, 6, 7, 8 and 9, or 1.6 M glycine-NaOH pH 10.4.

### Glucuronidation reactions

The incubation mixtures for glucuronidation assays contained 100 mM Tris-HCl buffer pH 7.4, 2.5 mM  $\text{MgCl}_2$ , 0.5 mM UDPGA, recombinant UGT or microsomes as the enzyme source and 0 – 15  $\mu$ M of the test aglycone substrate. When the incubation mixtures contained microsomes, alamethicin was used at a final concentration of 12.5  $\mu$ g/ml, but it was not included in the recombinant enzyme assays<sup>43</sup>. In the first experiments three negative control samples were tested, namely i) without the substrate 7-hydroxycoumarin derivative, ii) without the cofactor UDPGA, or iii) without the enzyme source. In subsequent experiments, the control samples lacked the enzyme source since it gave the highest fluorescence background. Preliminary experiments were done under different conditions than most of the later assays, namely in 2.5 ml of 100 mM phosphate buffer pH 7.4, containing 500  $\mu$ g pig liver microsomes, 1.0  $\mu$ M compound **6** and 0.5 mM UDPGA, at room temperature. Fluorescence spectra (excitation 200 - 420 nm; emission 400 – 600 nm) or fluorescence decrease at 390 nm excitation and 460 nm emission, were measured in these preliminary experiments, using a Shimadzu RF-5000 spectrofluorometer.

Most of the glucuronidation assays were carried out in 96 multiwell plate format, and incubations were carried out in 100  $\mu$ l and at 37°C, in the presence of Tris-HCl buffer pH 7.4, UDPGA and the tested 7-hydroxycoumarin derivative, at the indicated concentrations. Fluorescence decline in the multiwell plate experiments was monitored every other minute, for 40 min, using an excitation filter at 405 nm and detection at 460 nm, in a Victor2 1420 Multilabel counter (PerkinElmer, Life Sciences, Turku, Finland). The fluorescence values were transformed into molarity using the aglycone substrates for making the respective standard curves. Slopes of the substrate concentration decrease per minute were calculated using linear regression analysis, in which the linear part of the kinetic assay indicated the glucuronidation rate. Enzyme catalyzed glucuronidation rate was calculated by subtracting the blank value from the full reaction value. The intra-assay variability of the kinetic assays was 6 % when compound **6** was used as the aglycone substrate. Kinetic analyses were also performed in the same 96 multiwell plates format, with excitation filter at 405 nm and detection at 460 nm, using 6-8 different substrate concentrations per substrate and two different protein concentrations for both the wild-type and mutant UGT1A10. The higher concentrations, 13.5 mg/L for UGT1A10 and 12.0 mg/L for the UGT1A10 mutant, were used when the substrates were HFC, compounds **4** and **6**, whereas the lower protein concentrations, 6.75 and 6.0 mg/L for UGT1A10 and the mutant, respectively, were used when the substrates were compounds **1**, **2**, **3**, and **5**.

In end-point determinations, the glucuronidation reactions were stopped by the addition of 150  $\mu$ l 1.6 M glycine-NaOH buffer, pH 10.4, followed by fluorescence measurements at 405 nm excitation and 460 nm emission. There was a good correlation between kinetic and end-point assays (data not shown).

**HPLC-MS analysis of 7-hydroxy-3-triazolecoumarin glucuronide.** For further analysis of 7-hydroxy-3-triazolecoumarin glucuronide, 10  $\mu$ M of compound **6** were incubated in 100  $\mu$ l

of 100 mM Tris-HCl pH 7.4 buffer containing 5 mM  $\text{MgCl}_2$ , 1 mM UDPGA and either 30 - 40  $\mu\text{g}$  recombinant UGT, 30  $\mu\text{g}$  HLM or 20  $\mu\text{g}$  HIM, for 1 h at 37 C. The reactions were stopped by the addition of 300  $\mu\text{l}$  methanol, centrifugation and then the supernatant was divided into two. One part, 100  $\mu\text{l}$  supernatant, was mixed with 150  $\mu\text{l}$  1.6 M glycine-NaOH pH 10.4 and subjected to fluorescence measurements as described above for the 96-well plate. The other part, 250  $\mu\text{l}$  supernatant, was stored at - 20 C until analysis by HPLC-MS.

An Agilent 1200 Series Rapid Resolution LC System (Agilent Technologies, Waldbronn, Germany) was used for the chromatographic separation, equipped with a reversed-phase C8 column (Brownlee Supra, 3  $\mu\text{m}$ , 50  $\times$  2.1 mm, Perkin Elmer). The mobile phases were (A) 0.1% aqueous formic acid and (B) acetonitrile. A linear gradient from 10% to 90% B in five min was applied, followed by one min isocratic elution with 90% B and column re-equilibration, yielding a total analysis time of nine min. The flow rate was 0.3 mL/min, injection volume 3  $\mu\text{L}$  and column oven temperature 30  $^\circ\text{C}$ . For the MS detection, a Finnigan LTQ ion trap mass spectrometer (Thermo, San Jose, CA) was used in the positive electrospray (ESI) mode. A divert valve was used to direct eluent flow to the waste for 1 min at the beginning and at the end of the gradient run. The MS analysis was carried out using the following parameters: spray voltage 4 kV, sheath gas 30 (instrument units), aux gas 15, sweep gas 3, capillary temperature 250  $^\circ\text{C}$ , capillary voltage 43 V, tube lens 100 V. The collision energy used for MS/MS was 30 V. The acquired full scan MS range was m/z 60 – 600. Ions used for the detection of the aglycone and glucuronide conjugate were m/z 230  $[\text{M}+\text{H}]^+$  and m/z 406  $[\text{M}+\text{H}+176]^+$ , respectively. Data was acquired and processed using Xcalibur software package.

## Results

### Modeling UGT1A enzymes

Template structures for homology modeling of the UGT enzymes of subfamily 1A were selected based on sequence similarity, using the blast option in Uniprot. Structures that contained both the sugar-nucleotide cofactor and a small aglycone molecule were beneficial for the model and, therefore, structures (pdb-codes) 2C1Z/X, 2O6L, 3HBF, and 3WC4 were selected. The conserved lipophilic region that spans the endoplasmic reticulum membrane and ends in the “cytoplasmic tail” were excluded from the model because the focus of the model construction was on the catalytic site and its surrounding area. In addition, other structures outside the catalytic site of the model, including loops and amino acid side chain conformations, were not optimized. Optimizing efforts were considered detrimental for the quality of the models as the sequence similarity between the templates and the UGT sequences was very low. In other words, the models were not considered to be good enough for molecular dynamics simulations in order to evaluate binding energy or other kinetic parameters. On the other hand, an essential part of the model building was to predict binding of the 7-hydroxycoumarin derivatives so that glucuronidation will occur at the 7-hydroxyl group and for this purpose the models were adequate.

The homology models were used to design novel and UGT-selective fluorescent 7-hydroxycoumarin substrate molecules, whose fluorescence will decrease upon glucuronidation (Figure 1). Docking of the 7-hydroxycoumarin scaffolds (Figure 2A-C) into different UGT1A models yielded several possible conformations. One of them oriented the 7-hydroxy group toward the bound UDP-glucuronic acid (UDPGA) cofactor at the catalytic site and, simultaneously, the coumarin core was optimally placed into a nearby cavity in the catalytic site (Figure 2D). In our models, the coumarin scaffold could be stabilized through its

C2-carbonyl oxygen, accepting a hydrogen bond from Q101 in UGT1A8 (Figure 2C), UGT1A9 and UGT1A10 (Figure 2A). Even stronger stabilizing interactions could be formed between the coumarin carbonyl at C2 and R102 of UGT1A6 (Figure 2C). On the other hand, D103 in UGT1A1 (Figure 2B), E104 in UGT1A3 and UGT1A4, or P101 in UGT1A7, are not capable of forming similar stabilizing hydrogen bond interactions at this site, suggesting that the coumarin core would not be an optimal substrate for these UGTs. Furthermore, R103 of UGT1A7, UGT1A8 and UGT1A9, counteracted the stabilizing interactions and partially blocked the binding of the coumarin scaffold to these UGTs due to its size (Figure 2C). Unlike significantly bulkier R103 of UGT1A8 (Figure 2C), the Q103 of UGT1A10 at this site could donate a hydrogen bond to the oxygen at position 1 of the coumarin scaffold (Figure 2A).

[Figure 2]

Based on these homology models, there was an additional, but variable in size, free space available in the active site of each UGT1A enzyme, next to position 3 of the coumarin core. When combined with the 7-hydroxycoumarin docking site analyses (see above), this additional space was large enough in UGT1A1 and UGT1A10 to accommodate five- or six-membered ring substituents (Figure 2D). In contrast, a bulkier phenylalanine (F212) is present in the UGT1A6 model at this position, clearly hindering binding of any 3-substituted 7-hydroxycoumarins. The properties of this binding site were quite different also between UGT1A1 and UGT1A10. While UGT1A1 has a hydrophobic methionine (M213) facing this site (Figure 2B), UGT1A10 has a histidine at the corresponding site (H210; Figure 2A). On the opposite side of this additional space, UGT1A10 has an alanine (A100), while UGT1A1 has an asparagine (N102) aligned to the same position. This may mean that in UGT1A10 there is enough space for rather large 3-substituted 7-hydroxycoumarins, whereas UGT1A1 would have problems accommodating larger substitutions at this position of the 7-

hydroxycoumarin scaffold. At the other end of the UGT1As “spectrum”, UGT1A6 has a glutamic acid (E101) aligned at the same site, which would limit the cavity even further.

Based on docking of a virtual library into the UGT1A10 model, the most promising molecules were 7-hydroxycoumarin derivatives with the following substituents at the C3 position: 4-fluorophenyl (**1**), 4-hydroxyphenyl (**2**), 4-methoxyphenyl (**3**), 4-dimethylaminophenyl (**4**), 4-methylphenyl (**5**) or triazole (**6**). Among these, the triazole (**6**) derivative could be stabilized by H210 in UGT1A10, while the corresponding methionine in UGT1A1 (M213) would not be able to form hydrogen bonds with it. In contrast, the addition of a phenyl moiety to the C3-position would allow binding by both UGT1A1 and UGT1A10, as the hydrophobic methionine in UGT1A1 is quite an ideal companion, while the histidine in UGT1A10 could change its conformation according to the donor functionality, as with triazole. Based on these observations and considerations, the six new coumarin derivatives were designed and synthesized (Figure 3: compounds **1-6**). The selected compounds were made from inexpensive starting materials, producing 3-substituted coumarins with 5- or 6-membered rings.

[Figure 3]

### Glucuronidation of the 3-substituted 7-hydroxycoumarins

The absorbance and fluorescence spectra of compounds **1 – 6** were very similar showing, however, some differences in intensity as well as excitation and emission peaks among them (Figure 4A, Supplementary Figures 1 and 2, Supplementary Table 1.). The fluorescence was pH dependent, emitting strongly in neutral and alkaline solutions.

In the first glucuronidation experiments, the fluorescence intensity of all the C3 substituted 7-hydroxycoumarin derivatives, compounds **1 – 6**, decreased when they were incubated in the

presence of pig liver microsomes and UDPGA, in a buffer containing 100 mM Tris-HCl pH 7.4 and 5 mM MgCl<sub>2</sub> (Figure 4B). No significant fluorescence decrease was observed in the negative controls, namely in the absence of either microsomes, a coumarin derivative such as **6**, or UDPGA. The fluorescence changes were linearly dependent on the amount of microsomes (Figure 4C), indicating that the biosynthesis of C3 substituted 7-hydroxycoumarin derivatives to nonfluorescent glucuronide conjugates was catalyzed by one or more UDP-glucuronosyltransferase enzymes in the microsomes. The presence of alamethicin increased glucuronidation rates in this microsomal sample, whereas the addition of more than 5 % (v/v) dimethyl sulfoxide, acetonitrile or ethanol decreased it (Figure 4D). An example for glucuronide formation under such incubation condition, using **6** as the substrate, is presented in Figure S3.

[Figure 4]

The above results with **6** and pig liver microsomes suggested that the glucuronidation rates of the new 7-hydroxycoumarin derivatives could be accurately determined under our standardized assay conditions, using different enzyme sources. Subsequently, the glucuronidation rates of all the new C3 substituted 7-hydroxycoumarin derivatives by nearly all the human UGTs, including enzymes that are not commercially available, were determined (Figure 5). For comparison and additional controls, the glucuronidation of 7-hydroxycoumarin and 4-trifluoromethyl-7-hydroxycoumarin (HFC), that carry no C3 substitution, by the recombinant enzymes were also measured (Figure 5).

[Figure 5]

The human UGTs screen revealed that all six newly synthesized C3 substituted 7-hydroxycoumarins were glucuronidated by UGT1A10 more rapidly than by other UGT forms. Furthermore, **2**, **4**, **5** and **6** were selective for UGT1A10, as other UGTs catalyzed their

glucuronidation at very low rates. The remaining two new substrates, **1** and **3**, were glucuronidated, in addition to UGT1A10, also by UGT1A1, at rates of about 40 % and 20 %, respectively, of the corresponding UGT1A10 rate (Figure 5). The glucuronidation profiles of the new derivatives differed significantly from the control substrates, 7-hydroxycoumarin and HFC, which were glucuronidated primarily by UGT1A6 (7-hydroxycoumarin), or UGT1A6 and UGT1A10 (HFC), as well as by few other UGTs at lower rates (Figure 5).

In addition to recombinant UGTs, the glucuronidation rates of all the new C3 7-hydroxycoumarin derivatives, along with 7-hydroxycoumarin and HFC, were measured in human liver microsomes (HLM) and human intestinal microsomes (HIM). The results showed that all the new compounds were glucuronidated by HIM at higher rates than by HLM (Figure 6). Furthermore, **2**, **4** and **6** were not glucuronidated by HLM at all, or only at very low rates, whereas **3** and **5** were conjugated by HLM to about 20 – 25% of the rate exhibited by HIM. **1** was glucuronidated by HLM at about 40% of the corresponding rate in HIM (Figure 6). Kinetics of compound **6** glucuronidation confirmed that glucuronidation is more specific in intestinal than hepatic microsomes, as its  $K_m$ -value was 82 (49-115)  $\mu\text{M}$  and  $V_{\text{max}}$  4.0 (2.6-5.4)  $\mu\text{mol}/(\text{min} \cdot \text{g prot})$  in human hepatic microsomes and its  $K_m$ -value was 12 (8.8-15)  $\mu\text{M}$  and  $V_{\text{max}}$  3.5 (2.9-4.0)  $\mu\text{mol}/(\text{min} \cdot \text{g prot})$  in human intestinal microsomes. Adding albumin to incubation mixture increased both  $K_m$ - and  $V_{\text{max}}$ -values in intestinal microsomes. In sharp contrast to glucuronidation of the new 7-hydroxycoumarin derivatives, the “parent compound” 7-hydroxycoumarin, as well as HFC, were glucuronidated to much higher rates by HLM than by HIM (Figure 6).

[Figure 6]

### Effect of H210 to M210 mutation on UGT1A10 activity

The developed model, by being explicit about the role of certain key UGT1A10 residues in the binding of the designed 7-hydroxycoumarin derivatives, also allowed testing it by mutagenesis. Hence, we prepared mutant 1A10-H210M, a mutant of UGT1A10 in which H210 was changed to methionine, the corresponding residue in UGT1A1. The mutant was expressed in insect cells, similarly to all the other recombinant UGTs that were used in this study, and its activity toward the new 7-hydroxycoumarin derivatives was tested. This was combined with kinetic analyses of the glucuronidation of these compounds by both UGT1A10 and UGT1A10-H201M, side-by-side (Fig. 7 and Table 1). The results demonstrated clear effects of the mutation on the glucuronidation kinetics of most compounds. A decrease of  $V_{\max}$  occurred in all but **2** and **6**, in which the  $K_m$  values were considerably increased (Table 1). Changes in the  $K_m$  values of the other compounds were variable, however, an increase in the case of HFC, no change for **5** and a decrease in **1**, **3** and **4** (Table 1).

[Table 1.]

## Discussion

In this study we constructed predictive homology models for the human UGT1A enzymes in order to design selective substrates for them. The models indicated several key characteristics that differ among the active sites of individual UGT1A enzymes. These differences were exploited for the design and synthesis of six new 3-substituted 7-hydroxycoumarin derivatives. All the new compounds were good substrates for UGT1A10 and four of them, namely **2**, **4**, **5** and **6**, were selective substrates for this UGT (Fig. 5). Among the clear advantages of these new 7-hydroxycoumarin derivatives as UGT1A10 substrates are their extensive fluorescence and simple synthesis from low-cost starting materials that make them suitable for quick and convenient activity measurements in a high throughput format.

Currently, no high-resolution, or even low-resolution, structure of a full-length UGT is available from X-ray crystallography or cryo-electron microscopy. Although their 3D-model construction is challenging, homology models of UGT1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9 and 1A10 were constructed in this study. These models suggested that the active site of UGT1A10 is sufficiently different from the other UGTs to enable design and synthesis of selective substrates for it.

We had two goals in designing these substrates: they should be selective for UGT1A10 and determination of their glucuronidation should be based on easily measurable fluorescence change during the assay. As a starting point, the 7-hydroxycoumarin scaffold was selected, since it is a common UGT substrate and its derivatives have intense fluorescence<sup>44</sup>. In addition, 7-hydroxycoumarin and 7-hydroxy-4-trifluoromethylcoumarin have both been shown to be glucuronidated by several different UGTs<sup>25</sup>. The hydroxyl group of 7-hydroxycoumarin was oriented toward the UDPGA in the active site of the UGT1A10 model, indicating that there is space in the active site for an additional six or five ring substituent at

position C3 of the 7-hydroxycoumarin scaffold (Figure 2). Thus, we synthesized six new UGT1A10 substrates, all of which were 7-hydroxycoumarin derivatives with various substituents at position C3 of the coumarin scaffold.

All the new 7-hydroxycoumarin derivatives are highly fluorescent and their fluorescence decreases upon enzymatic glucuronidation (see Figure 4 for an example with compound **6**). A concern in these assays was non-linearity of the fluorescence at substrate concentrations above 20  $\mu$ M. However, fluorescence changes of these substrates were selective, sensitive and quantitative enough for measurements below this concentration limit, as the amount of UGT1A10 enzyme could be adjusted to yield linear glucuronidation rates.

The selectivities of the 7-hydroxycoumarin derivatives for UGT1A10 differed substantially. While some of them, such as **2**, **4** and **6**, were highly selective, others, like **1** and **3**, were also glucuronidated by UGT1A1 at considerable rates (Figure 5). Previous studies have shown that fluorescent derivatives of N-butyl-4-phenyl-1,8-naphthalimide are UGT1A1 selective substrates<sup>45</sup>.

Since UGT1A10 is an extrahepatic enzyme expressed at high level in the intestine,<sup>11</sup> the results obtained with recombinant UGTs could be tested with HLM and HIM. Although these microsomal preparations contain several different UGTs each, HLM lacks a functional UGT1A10 while HIM contains it<sup>11</sup>. Indeed, the glucuronidation rates in HLM of **4** and **6**, as well as **2**, were very low or below the detection limit. Glucuronidation of **1**, **3** and **5** took place in HLM at rates up to 40% of the rates in HIM (Figure 6). These results also suggest which of the new compounds would be most useful for studies on UGT1A10 activity in samples from human tissues that express or may express this enzyme. The current results point at **2**, **4** and **6** as good candidates, **2** due to the lack of detectable activity in HLM, **4** based on the combination of high rate with high selectivity, and **6** due to its high selective

1  
2  
3 fluorescence intensity (Figure 6 and supplementary Figures S1 and S2). It may be added here  
4  
5 that we recently reported that the commonly used commercial UGT1A10 has low activity<sup>13</sup>.  
6  
7 In this study we have used the UGT1A10-H preparation, not the commercial UGT1A10.  
8  
9 Researches should not expect to get similar results to those reported here for UGT1A10 when  
10  
11 working with the commonly used commercial UGT1A10. On the other hand, experiments  
12  
13 with commercial HIM and HLM are expected to reproduce the current results.  
14  
15

16  
17 It is interesting to understand why **6** has a remarkably lower (less than 30 %) intrinsic  
18  
19 glucuronidation clearance ( $V_{\max}/K_m$ ) by UGT1A10 than the other new 7-hydroxycoumarin  
20  
21 derivatives, **1 – 5** (Table 1). Examination of the substituents at C3 suggests that **6** with a  
22  
23 triazole derivative at C3 was glucuronidated less efficiently than derivatives containing  
24  
25 hydrophobic or other types of hydrophilic substituents. The reason for this could be that the  
26  
27 triazole causes stronger interactions than the other substituents in the active site of  
28  
29 UGT1A10, resulting in slower release of the formed glucuronide.  
30  
31

32  
33 The present modeling work indicates specific residues that are expected to lead to substrate  
34  
35 selectivity of UGT1A10. We have tested one of the predicted residues, H210, by changing it  
36  
37 to M210, the corresponding residue in UGT1A1, expressed the mutant UGT1A10-M210 and  
38  
39 studied the glucuronidation kinetics of all the new compounds by both the wildtype (i.e.  
40  
41 UGT1A10-H210) and mutant enzymes. The results revealed changes in the  $K_m$  and/or  $V_{\max}$   
42  
43 values of the glucuronidation kinetics of all the compounds, but with clear differences among  
44  
45 them (Figure 7 and Table 1). Another unexpected observation was the effect of the mutation  
46  
47 on HFC glucuronidation rate, which may suggest that the effect of the mutation is larger than  
48  
49 expected by the model, or that substrate(s) binding by UGT1A10 (also) involves an induced  
50  
51 fit mechanism.  
52  
53  
54  
55  
56  
57  
58  
59  
60

In conclusion, in this study 3D molecular models of the UGT1As were constructed and used for the design and synthesis of six new fluorescent UGT substrates. A new multiwell-based method that takes advantage of the fluorescence of the compounds and their fluorescence decrease upon glucuronidation, was established to measure glucuronidation rates. Of the new compounds, 4-dimethylaminophenyl (**4**) and triazole (**6**) C3 substituted 7-hydroxycoumarins appeared to be the most selective substrates for UGT1A10, an important and often underestimated extrahepatic human UGT. It is concluded that the selectivity of the new coumarin derivatives for UGT1A10 depends on the chemical character of their substituent at C3. These new compounds should enable better, faster, and easier determination of UGT1A10 activity in tissues than was earlier possible. In addition, their further chemical modification could stimulate the development of new tools to explore the active site of different UGT enzymes.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Acknowledgements**

We thank Ms Hannele Jaatinen for excellent expertise in laboratory work. Finnish IT Centre for Science (CSC) is acknowledged for generous computational grant (O.T.P.: jyy2516 and jyy2585). We thank Johanna Mosorin for her valuable contribution in the preparation of recombinant UGTs. The financial support of the academy of Finland (grant no. 137589) and the Sigrid Juselius Foundation (grant no. 4704583) are highly acknowledged.

**Author Contributions**

R.O.J, H.R., and O.T.P designed the study. S.R., S.N. and O.T.P. performed the modelling. S.K. and J.H. performed the synthesis of molecules. A.P. performed HPLC-MS analysis. R.O.J. performed the experimental measurements. M.F. provided the UGT enzymes and with J.T. prepared the mutant. All the authors contributed to writing of the manuscript.

**Declaration of Interest**

The authors declare no conflict of interests.

Table 1. Michaelis-Menten (MM) kinetic constants of UGT1A10 and UGT1A10mutant catalyzed 7-hydroxyl glucuronidation for the 3-substituted 7-hydroxycoumarins.

	<b>UGT1A10</b>				<b>UGT1A10mutant</b>			
Compound	K <sub>m</sub> (95 % confidence interval) [μM]	V <sub>max</sub> (95 % confidence interval) [μmol/min/g prot]	V <sub>max</sub> / K <sub>m</sub> [L/min/g prot]	Non-linear MM model R <sup>2</sup>	K <sub>m</sub> (95 % confidence interval) [μM]	V <sub>max</sub> (95 % confidence interval) [μmol/min/g prot]	V <sub>max</sub> / K <sub>m</sub> [L/min/g prot]	Non-linear MM model R <sup>2</sup>
<b>1</b>	10.7 (1.7-19.6)	31 (17-46)	2.9	0.9813	3.5 (0-9.3)	8.7 (3.4-14)	2.5	0.8726
<b>2</b>	2.2 (1-3.4)	5.9 (4.9-6.9)	2.7	0.9788	7.8 (5.5-10.2)	6.3 (5.4-7.3)	0.81	0.9965
<b>3</b>	8.3 (0-31.4)	22.3 (0 – 53.4)	2.7	0.8028	3.8 (0.97-6.7)	9.5 (6.8-12.3)	2.5	0.9695
<b>4</b>	2.8 (0-6.5)	15.3 (7.3-24)	5.5	0.9215	4.7 (1.5-7.9)	6.5 (4.4-8.6)	1.4	0.9846
<b>5</b>	2.8 (0.7-4.9)	16.2 (12-20)	5.8	0.9571	4.6 (1.5-7.8)	5.9 (4.1-7.6)	1.3	0.9750
<b>6</b>	7.0 (3.1-11)	5.3 (3.7-8)	0.76	0.9879	26.8 (0-80)	6.3 (0-15.9)	0.24	0.9733
<b>HFC</b>	14 (10.7-17.3)	15.1 (12.7-17.5)	1.1	0.9991	32.9 (0-102)	11.7 (0-31.7)	0.36	0.9781

## Figure legends

Figure 1. Glucuronidation of 7-hydroxycoumarin derivatives. Fluorescent 3-substituted 7-hydroxycoumarins are glucuronidated to non-fluorescent glucuronide conjugates by UGT enzymes. The decrease in fluorescence can be measured conveniently in different kinds of experimental setups.

Figure 2. Docking of 7-hydroxycoumarin and its derivatives into the UGT1A10 model. (A) Molecular docking placed the 7-hydroxycoumarin with the 7-hydroxy facing the catalytic site formed by H37 and UDPGA, enabling the glucuronidation reaction and the subsequent decrease in fluorescence. (B) In UGT1A1, D103 and L106 are not capable of forming similar beneficial interactions with the coumarin core as the UGT1A10 model. Although N102 might be able to form beneficial interactions with certain compounds, the cavity might not be large enough for more sizable substitutions due to N102 and M213. (C) UGT1A8 has otherwise the same amino acid residues aligning the cavity as UGT1A10, except for R103. Due to its size, R103 might impair the binding of the coumarin core. (D) **6** fills the binding cavity (orange solvent accessible surface) of the UGT1A10 model (green solvent accessible surface). Docking suggests that the 7-hydroxycoumarin and **6** have a similar binding mode at their identical core. In addition, the C3 substituent of **6** fits tightly to the additional space at the outward facing end of the binding cavity.

Figure 3. Novel (**1-6**) and control 7-hydroxycoumarin and 7-hydroxy-4-trifluoromethylcoumarin (HCF) substrates of UGT1A enzymes in this study.

Figure 4. Decrease of 7-hydroxycoumarin fluorescence during glucuronidation. Excitation and emission fluorescence spectra of 0.1  $\mu$ M 7-hydroxy-3-triazolecoumarin at 100 mM phosphate pH 7.4 buffer (panel A); decrease in 10  $\mu$ M 7-hydroxy-3-triazolecoumarin fluorescence in the presence of 0.7 mg/mL pig liver microsomal protein, 0.5 mM UDPGA, 5

mM  $\text{MgCl}_2$  and 100 mM Tris-HCL pH 7.4 (panel B); effect of the amount of microsomal protein on the decrease in fluorescence (panel C); effect of solvents and alamethicin on the decrease in fluorescence (panel D). Corresponding results were obtained with other C7 substituted 7-hydroxycoumarin derivatives.

Figure 5. Glucuronidation of C3 substituted 7-hydroxycoumarins by human UGTs. Glucuronidation was determined at 10  $\mu\text{M}$  aglycone concentration.

Figure 6. Glucuronidation of C3 substituted 7-hydroxycoumarins by human intestinal and hepatic microsomes. Glucuronidation was determined at 10  $\mu\text{M}$  aglycone concentration.

Figure 7. Michaelis-Menten kinetics of UGT1A10 (open circle) and UGT1A10 mutant (closed circle) catalyzed 7-hydroxyl glucuronidation for the 3-substituted 7-hydroxycoumarins (**1** – **7** and HFC). The data are from one experiment and the analyzed data are shown in table 1.

## Supporting information

Supplementary figures and tables.

## References

1. Jones, C. R.; Hatley, O. J.; Ungell, A. L.; Hilgendorf, C.; Peters, S. A.; Rostami-Hodjegan, A., Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination. *Aaps J* **2016**, *18* (3), 589-604.
2. Gonzalez, F. J.; Coughtrie, M.; Tukey, R. H., Drug Metabolism. In *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 12th edition ed.; Brunton, L. L.; Chabner, B.; Knollman, B., Eds. McGraw-Hill: New York, 2011; pp 123-143.
3. Mizuma, T., Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. *Int J Pharmaceut* **2009**, *378* (1-2), 140-141.
4. Ritter, J. K., Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. *Expert Opin Drug Metab Toxicol* **2007**, *3* (1), 93-107.
5. Wu, B. J.; Kulkarni, K.; Basu, S.; Zhang, S. X.; Hu, M., First-Pass Metabolism via UDP-Glucuronosyltransferase: a Barrier to Oral Bioavailability of Phenolics. *Journal of pharmaceutical sciences* **2011**, *100* (9), 3655-3681.
6. Testa, B.; Kramer, S. D., The biochemistry of drug metabolism--an introduction: part 5. Metabolism and bioactivity. *Chemistry & biodiversity* **2009**, *6* (5), 591-684.
7. Kaivosaari, S.; Finel, M.; Koskinen, M., N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. *Xenobiotica* **2011**, *41* (8), 652-69.
8. Rowland, A.; Miners, J. O.; Mackenzie, P. I., The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. *The international journal of biochemistry & cell biology* **2013**, *45* (6), 1121-32.
9. Court, M. H.; Zhang, X. L.; Ding, X. X.; Yee, K. K.; Hesse, L. M.; Finel, M., Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. *Xenobiotica* **2012**, *42* (3), 266-277.
10. Ohno, S.; Nakajin, S., Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction. *Drug Metabolism and Disposition* **2009**, *37* (1), 32-40.
11. Sato, Y.; Nagata, M.; Tetsuka, K.; Tamura, K.; Miyashita, A.; Kawamura, A.; Usui, T., Optimized Methods for Targeted Peptide-Based Quantification of Human Uridine 5'-Diphosphate-Glucuronosyltransferases in Biological Specimens Using Liquid Chromatography-Tandem Mass Spectrometry. *Drug Metabolism and Disposition* **2014**, *42* (5), 885-889.
12. Hu, D. G.; Meech, R.; McKinnon, R. A.; Mackenzie, P. I., Transcriptional regulation of human UDP-glucuronosyltransferase genes. *Drug Metab Rev* **2014**, *46* (4), 421-58.
13. Troberg, J.; Jarvinen, E.; Ge, G. B.; Yang, L.; Finel, M., UGT1A10 Is a High Activity and Important Extrahepatic Enzyme: Why Has Its Role in Intestinal Glucuronidation Been Frequently Underestimated? *Mol Pharm* **2016**.
14. Oda, S.; Kato, Y.; Hatakeyama, M.; Iwamura, A.; Fukami, T.; Kume, T.; Yokoi, T.; Nakajima, M., Evaluation of expression and glycosylation status of UGT1A10 in Supersomes and intestinal epithelial cells with a novel specific UGT1A10 monoclonal antibody. *Drug Metab Dispos* **2017**, *45* (9), 1027-1034.
15. Hoglund, C.; Sneitz, N.; Radomska-Pandya, A.; Laakonen, L.; Finel, M., Phenylalanine 93 of the human UGT1A10 plays a major role in the interactions of the enzyme with estrogens. *Steroids* **2011**, *76* (13), 1465-1473.

16. Kallionpää, R. A.; Jarvinen, E.; Finel, M., Glucuronidation of estrone and 16 $\alpha$ -hydroxyestrone by human UGT enzymes: The key roles of UGT1A10 and UGT2B7. *The Journal of steroid biochemistry and molecular biology* **2015**, *154*, 104-111.
17. Itaaho, K.; Mackenzie, P. I.; Ikushiro, S.; Miners, J. O.; Finel, M., The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases. *Drug Metab Dispos* **2008**, *36* (11), 2307-15.
18. Sneitz, N.; Vahermo, M.; Mosorin, J.; Laakkonen, L.; Poirier, D.; Finel, M., Regiospecificity and stereospecificity of human UDP-glucuronosyltransferases in the glucuronidation of estriol, 16-epiestriol, 17-epiestriol, and 13-epiestradiol. *Drug Metab Dispos* **2013**, *41* (3), 582-91.
19. Itaaho, K.; Court, M. H.; Uutela, P.; Kostainen, R.; Radomska-Pandya, A.; Finel, M., Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10. *Drug Metab Dispos* **2009**, *37* (4), 768-75.
20. Raunio, H.; Kuusisto, M.; Juvonen, R. O.; Pentikainen, O. T., Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes. *Front Pharmacol* **2015**, *6*, 123.
21. Kirchmair, J.; Goller, A. H.; Lang, D.; Kunze, J.; Testa, B.; Wilson, I. D.; Glen, R. C.; Schneider, G., Predicting drug metabolism: experiment and/or computation? *Nature reviews. Drug discovery* **2015**, *14* (6), 387-404.
22. Dai, Z. R.; Feng, L.; Jin, Q.; Cheng, H.; Li, Y.; Ning, J.; Yu, Y.; Ge, G. B.; Cui, J. N.; Yang, L., A practical strategy to design and develop an isoform-specific fluorescent probe for a target enzyme: CYP1A1 as a case study. *Chem Sci* **2017**, *8* (4), 2795-2803.
23. Dai, Z. R.; Ge, G. B.; Feng, L.; Ning, J.; Hu, L. H.; Jin, Q.; Wang, D. D.; Lv, X.; Dou, T. Y.; Cui, J. N.; Yang, L., A Highly Selective Ratiometric Two-Photon Fluorescent Probe for Human Cytochrome P450 1A. *J Am Chem Soc* **2015**, *137* (45), 14488-95.
24. Miley, M. J.; Zielinska, A. K.; Keenan, J. E.; Bratton, S. M.; Radomska-Pandya, A.; Redinbo, M. R., Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. *J Mol Biol* **2007**, *369* (2), 498-511.
25. Rahikainen, T.; Hakkinen, M. R.; Finel, M.; Pasanen, M.; Juvonen, R. O., A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human UDP-glucuronosyltransferases and liver microsomes. *Xenobiotica* **2013**, *43* (10), 853-61.
26. Modolo, L. V.; Li, L.; Pan, H.; Blount, J. W.; Dixon, R. A.; Wang, X., Crystal structures of glycosyltransferase UGT78G1 reveal the molecular basis for glycosylation and deglycosylation of (iso)flavonoids. *J Mol Biol* **2009**, *392* (5), 1292-302.
27. Hiromoto, T.; Honjo, E.; Tamada, T.; Noda, N.; Kazuma, K.; Suzuki, M.; Kuroki, R., Crystal structure of UDP-glucose:anthocyanidin 3-O-glucosyltransferase from *Clitoria ternatea*. *J Synchrotron Radiat* **2013**, *20* (Pt 6), 894-8.
28. Offen, W.; Martinez-Fleites, C.; Yang, M.; Kiat-Lim, E.; Davis, B. G.; Tarling, C. A.; Ford, C. M.; Bowles, D. J.; Davies, G. J., Structure of a flavonoid glucosyltransferase reveals the basis for plant natural product modification. *EMBO J* **2006**, *25* (6), 1396-405.
29. Lehtonen, J. V.; Still, D. J.; Rantanen, V. V.; Ekholm, J.; Bjorklund, D.; Iftikhar, Z.; Huhtala, M.; Repo, S.; Jussila, A.; Jaakkola, J.; Pentikainen, O.; Nyronen, T.; Salminen, T.; Gyllenberg, M.; Johnson, M. S., BODIL: a molecular modeling environment for structure-function analysis and drug design. *J Comput Aided Mol Des* **2004**, *18* (6), 401-19.
30. Johnson, M. S.; Overington, J. P., A structural basis for sequence comparisons. An evaluation of scoring methodologies. *J Mol Biol* **1993**, *233* (4), 716-38.
31. Sali, A.; Blundell, T. L., Comparative protein modelling by satisfaction of spatial restraints. *J Mol Biol* **1993**, *234* (3), 779-815.
32. Niinivehmas, S. P.; Salokas, K.; Latti, S.; Raunio, H.; Pentikainen, O. T., Ultrafast protein structure-based virtual screening with Panther. *J Comput Aided Mol Des* **2015**, *29* (10), 989-1006.
33. Korb, O.; Stutzle, T.; Exner, T. E., Empirical scoring functions for advanced protein-ligand docking with PLANTS. *J Chem Inf Model* **2009**, *49* (1), 84-96.

34. Niinivehmas, S. P.; Manivannan, E.; Rauhamaki, S.; Huuskonen, J.; Pentikainen, O. T., Identification of estrogen receptor alpha ligands with virtual screening techniques. *J Mol Graph Model* **2016**, *64*, 30-9.
35. Kirkiacharian, S.; Lormier, A. T.; Resche-Rigon, M.; Bouchoux, F.; Cerede, E., [Synthesis and binding affinity of 3-aryl-7-hydroxycoumarins to human alpha and beta estrogen receptors]. *Ann Pharm Fr* **2003**, *61* (1), 51-6.
36. Buuhoi, N. P.; Ekert, B.; Royer, R., Bz-Hydroxylated-3-Aryl-Coumarins and 3,4-Diaryl-Coumarins. *J Org Chem* **1954**, *19* (9), 1548-1552.
37. Kurkela, M.; Garcia-Horsman, J. A.; Luukkanen, L.; Morsky, S.; Taskinen, J.; Baumann, M.; Kostainen, R.; Hirvonen, J.; Finel, M., Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. *J Biol Chem* **2003**, *278* (6), 3536-44.
38. Kuuranne, T.; Aitio, O.; Vahermo, M.; Elovaara, E.; Kostainen, R., Enzyme-assisted synthesis and structure characterization of glucuronide conjugates of methyltestosterone (17 alpha-methylandro-4-en-17 beta-ol-3-one) and nandrolone (estr-4-en-17 beta-ol-3-one) metabolites. *Bioconjugate chemistry* **2002**, *13* (2), 194-9.
39. Sneitz, N.; Court, M. H.; Zhang, X.; Laajanen, K.; Yee, K. K.; Dalton, P.; Ding, X.; Finel, M., Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3. *Pharmacogenet Genomics* **2009**, *19* (12), 923-34.
40. Kurkela, M.; Patana, A. S.; Mackenzie, P. I.; Court, M. H.; Tate, C. G.; Hirvonen, J.; Goldman, A.; Finel, M., Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6. *Pharmacogenet Genomics* **2007**, *17* (2), 115-26.
41. Lang, M. A.; Gielen, J. E.; Nebert, D. W., Genetic evidence for many unique liver microsomal P-450-mediated monooxygenase activities in heterogeneic stock mice. *J Biol Chem* **1981**, *256* (23), 12068-75.
42. Kuuranne, T.; Kurkela, M.; Thevis, M.; Schanzer, W.; Finel, M.; Kostainen, R., Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases. *Drug Metab Dispos* **2003**, *31* (9), 1117-24.
43. Zhang, H.; Tolonen, A.; Rousu, T.; Hirvonen, J.; Finel, M., Effects of cell differentiation and assay conditions on the UDP-glucuronosyltransferase activity in Caco-2 cells. *Drug Metab Dispos* **2011**, *39* (3), 456-64.
44. Lavis, L. D.; Raines, R. T., Bright building blocks for chemical biology. *Acs Chem Biol* **2014**, *9* (4), 855-66.
45. Lv, X.; Feng, L.; Ai, C. Z.; Hou, J.; Wang, P.; Zou, L. W.; Cheng, J.; Ge, G. B.; Cui, J. N.; Yang, L., A Practical and High-Affinity Fluorescent Probe for Uridine Diphosphate Glucuronosyltransferase 1A1: A Good Surrogate for Bilirubin. *J Med Chem* **2017**, *60* (23), 9664-9675.




Figure 1. Glucuronidation of 7-hydroxycoumarin derivatives. Fluorescent 3-substituted 7-hydroxycoumarins are glucuronidated to non-fluorescent glucuronide conjugates by UGT enzymes. The decrease in fluorescence can be measured conveniently in different kinds of experimental setups.

338x190mm (96 x 96 DPI)




Figure 2. Docking of 7-hydroxycoumarin and its derivatives into the UGT1A10 model. (A) Molecular docking placed the 7-hydroxycoumarin with the 7-hydroxy facing the catalytic site formed by H37 and UDPGA, enabling the glucuronidation reaction and the subsequent decrease in fluorescence. (B) In UGT1A1, D103 and L106 are not capable of forming similar beneficial interactions with the coumarin core as the UGT1A10 model. Although N102 might be able to form beneficial interactions with certain compounds, the cavity might not be large enough for more sizable substitutions due to N102 and M213. (C) UGT1A8 has otherwise the same amino acid residues aligning the cavity as UGT1A10, except for R103. Due to its size, R103 might impair the binding of the coumarin core. (D) 6 fills the binding cavity (orange solvent accessible surface) of the UGT1A10 model (green solvent accessible surface). Docking suggests that the 7-hydroxycoumarin and 6 have a similar binding mode at their identical core. In addition, the C3 substituent of 6 fits tightly to the additional space at the outward facing end of the binding cavity.

1252x1570mm (72 x 72 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3. Novel (1-6) and control 7-hydroxycoumarin and 7-hydroxy-4-trifluoromethylcoumarin (HCF) substrates of UGT1A enzymes in this study.

338x190mm (96 x 96 DPI)




Figure 4. Decrease of 7-hydroxycoumarin fluorescence during glucuronidation. Excitation and emission fluorescence spectra of 0.1  $\mu\text{M}$  7-hydroxy-3-triazolecoumarin at 100 mM phosphate pH 7.4 buffer (panel A); decrease in 10  $\mu\text{M}$  7-hydroxy-3-triazolecoumarin fluorescence in the presence of 0.7 mg/mL pig liver microsomal protein, 0.5 mM UDPGA, 5 mM  $\text{MgCl}_2$  and 100 mM Tris-HCL pH 7.4 (panel B); effect of the amount of microsomal protein on the decrease in fluorescence (panel C); effect of solvents and alamethicin on the decrease in fluorescence (panel D). Corresponding results were obtained with other C7 substituted 7-hydroxycoumarin derivatives.

338x190mm (96 x 96 DPI)




Figure 5. Glucuronidation of C3 substituted 7-hydroxycoumarins by human UGTs. Glucuronidation was determined at 10 μM aglycone concentration.

338x190mm (96 x 96 DPI)




Figure 6. Glucuronidation of C3 substituted 7-hydroxycoumarins by human intestinal and hepatic microsomes. Glucuronidation was determined at 10  $\mu$ M aglycone concentration.

338x190mm (96 x 96 DPI)





Figure 7. Michaelis-Menten kinetics of UGT1A10 (open circle) and UGT1A10 mutant (closed circle) catalyzed 7-hydroxyl glucuronidation for the 3-substituted 7-hydroxycoumarins (1 – 7 and HFC). The data are from one experiment and the analyzed data are shown in table 1.

338x190mm (96 x 96 DPI)



Graphic for manuscript

338x190mm (96 x 96 DPI)